ET-02, a new hairloss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.
A user's progress with treating their hairloss, including using finasteride, minoxidil, retinoic acid, dermapenning twice weekly and ket 2% shampoo two to three times per week. Other users offered advice such as not derma penning too often or shaving the area bald for a couple of months.
Stopping finasteride often leads to rapid hairloss, returning to a genetic baseline, as the drug temporarily halts hairloss and promotes regrowth. The discussion explores the complexity of hairloss, suggesting that factors beyond DHT, such as genetics and scalp conditions, may play a role.
Concerns about the potential systemic effects and safety of PP405 for hairloss, with discussions on its comparison to existing treatments like finasteride and minoxidil. Users express skepticism about untested research chemicals and emphasize the importance of clinical trials to ensure safety and efficacy.
Androgenetic alopecia is caused by DHT affecting hair growth. Finasteride and minoxidil are used to manage hairloss by blocking DHT and promoting hair growth.